HUTCHMED (NASDAQ:HCM) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a research note published on Tuesday.

Separately, HSBC lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday.

HUTCHMED Price Performance

HCM stock opened at $13.09 on Tuesday. The company has a 50 day simple moving average of $14.51 and a 200 day simple moving average of $15.25. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $21.50. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors have recently added to or reduced their stakes in the business. Vident Advisory LLC grew its holdings in HUTCHMED by 78.3% during the 1st quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock worth $297,000 after acquiring an additional 8,664 shares during the last quarter. XY Capital Ltd grew its holdings in HUTCHMED by 142.4% during the 1st quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock worth $1,702,000 after acquiring an additional 66,460 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in HUTCHMED by 31.4% during the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock worth $367,000 after acquiring an additional 5,829 shares during the last quarter. Summit Trail Advisors LLC grew its holdings in HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company’s stock worth $212,000 after acquiring an additional 1,004 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of HUTCHMED by 49.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company’s stock valued at $39,000 after purchasing an additional 899 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.